세계의 플루오로퀴놀론 시장 예측(-2032년) : 유형, 스펙트럼, 투여 경로, 세대, 적응증, 지역별 세계 분석

According to Stratistics MRC, the Global Fluoroquinolones Market is accounted for $4.95 billion in 2025 and is expected to reach $8.05 billion by 2032 growing at a CAGR of 7.2% during the forecast period. Fluoroquinolones represent a group of synthetic antibiotics known for their broad activity against bacterial infections. Their primary action involves blocking DNA gyrase and topoisomerase IV, enzymes necessary for bacterial DNA processes. They are often prescribed for infections of the lungs, urinary tract, digestive system, and skin. While effective and convenient for oral administration, fluoroquinolones must be used carefully because of associated risks such as tendon rupture, nerve complications, and antibiotic resistance development.

According to the World Health Organization report in 2023, the highest number of new tuberculosis (TB) cases were reported in the Southeast Asia region, accounting for 45.0% of total cases, and amongst these, approximately 87.0% of new TB cases.

Market Dynamics:

Driver:

Rising prevalence of bacterial infections

As diagnostic capabilities improve and awareness of antimicrobial resistance grows, healthcare providers are prioritizing broad-spectrum agents for rapid intervention. Fluoroquinolones are increasingly used in both inpatient and outpatient settings due to their efficacy against gram-negative and gram-positive pathogens. Technological advancements in molecular diagnostics are enabling faster pathogen identification, supporting targeted antibiotic use. The aging population and rise in immunocompromised patients are further contributing to infection rates and antibiotic consumption. This growing clinical burden is driving sustained investment in next-generation fluoroquinolone formulations and delivery systems.

Restraint:

Severe side effects and safety concerns

Regulatory agencies like the FDA and EMA have issued black-box warnings and usage restrictions, impacting physician prescribing behavior. The integration of pharmacovigilance platforms and AI-driven adverse event tracking is helping monitor safety profiles more rigorously. Emerging research on long-term toxicity and microbiome disruption is prompting calls for more selective use. These concerns are slowing market expansion, especially in regions with stringent drug approval frameworks. As a result, manufacturers are investing in reformulated compounds and risk-mitigation strategies to restore clinical confidence.

Opportunity:

Rising demand for outpatient antibiotic treatments

The shift toward outpatient care is accelerating demand for oral fluoroquinolones that offer convenience and broad-spectrum coverage. Telemedicine platforms and remote diagnostics are enabling faster prescription workflows, especially for uncomplicated infections. Innovations in extended-release formulations and patient-friendly dosing regimens are improving adherence and therapeutic outcomes. Healthcare systems are increasingly favouring cost-effective outpatient treatments to reduce hospital burden and improve resource allocation. In emerging markets, rising access to primary care and digital health tools is expanding antibiotic reach beyond urban centres. This trend is opening new opportunities for tailored packaging, e-pharmacy distribution, and mobile health integration.

Threat:

Increasing generic competition

Patent expirations have led to a proliferation of low-cost alternatives, particularly in high-volume segments like ciprofloxacin and levofloxacin. Regulatory support for generic approvals and streamlined bioequivalence testing is accelerating market entry. Digital procurement platforms and centralized hospital tenders are favouring bulk purchases of generics over branded options. To remain competitive, originator companies are focusing on differentiated formulations, combination therapies, and lifecycle management strategies. However, without clear clinical superiority, branded fluoroquinolones risk losing ground in both mature and emerging markets.

Covid-19 Impact

The COVID-19 pandemic disrupted antibiotic supply chains and altered prescribing patterns, especially during peak hospitalization periods. While fluoroquinolones were not frontline antivirals, they were used to manage secondary bacterial infections in COVID patients. Lockdowns and manufacturing delays led to temporary shortages, prompting governments to reassess antibiotic stockpiling and distribution protocols. Regulatory bodies introduced emergency use pathways and fast-track approvals for essential antimicrobials. Post-pandemic strategies now emphasize supply chain resilience, antimicrobial stewardship, and integration of AI in infection surveillance.

The oral fluoroquinolones segment is expected to be the largest during the forecast period

The oral fluoroquinolones segment is expected to account for the largest market share during the forecast period, due to its widespread use in treating community-acquired infections. These formulations offer high bioavailability, ease of administration, and broad-spectrum efficacy, making them ideal for outpatient care. Technological innovations in tablet coatings and controlled-release mechanisms are enhancing patient compliance and minimizing gastrointestinal side effects. Hospitals and clinics are increasingly adopting oral regimens to reduce inpatient stays and healthcare costs. The rise of e-pharmacy platforms and mobile health apps is further boosting access to oral antibiotics. As demand for decentralized treatment grows, oral fluoroquinolones continue to lead in both volume and revenue.

The respiratory tract infections segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the respiratory tract infections segment is predicted to witness the highest growth rate, fuelled by rising incidence and diagnostic improvements. Fluoroquinolones are often prescribed for bronchitis, pneumonia, and sinusitis due to their potent action against respiratory pathogens. Advances in point-of-care testing and AI-assisted radiology are enabling quicker diagnosis and targeted therapy. Seasonal outbreaks and air pollution-related complications are increasing antibiotic prescriptions in urban centers. Healthcare providers are adopting fluoroquinolones for resistant strains where first-line treatments fail. This segment is also benefiting from clinical trials exploring novel combinations and inhalable formulations for enhanced pulmonary delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by high infection rates and expanding healthcare infrastructure. Countries like China, India, and Indonesia are witnessing increased antibiotic consumption due to population density and limited sanitation. Government initiatives are promoting local manufacturing and generic production to meet rising demand. The region is also embracing digital health platforms and mobile diagnostics to improve rural access to fluoroquinolones. Strategic collaborations between global pharma firms and regional distributors are enhancing supply chain efficiency.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, supported by advanced healthcare systems and robust R&D investment. The U.S. and Canada are leading in antimicrobial stewardship, precision diagnostics, and AI-driven prescription analytics. Regulatory agencies are streamlining approval pathways for novel fluoroquinolone derivatives and combination therapies. Hospitals are integrating electronic health records and predictive algorithms to optimize antibiotic use and reduce resistance. The region also benefits from strong reimbursement frameworks and widespread adoption of outpatient care models. As innovation in drug delivery and formulation accelerates, North America continues to shape the future of fluoroquinolone therapeutics.

Key players in the market

Some of the key players profiled in the Fluoroquinolones Market include Bayer AG, Aurobindo Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Novartis AG, Glenmark Pharmaceuticals, Sanofi, Mylan N.V., GlaxoSmithKline plc, Cipla Ltd., Johnson & Johnson, Lupin Pharmaceuticals, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Key Developments:

In September 2025, Bayer announced the launch of Bayer Co.Lab AdVenture, a new platform for its Bayer Co.Lab global life sciences incubator network, which aims to connect venture capital partners globally. Bayer Co.Lab AdVenture bridges tenants of high-potential biotech startups with leading venture capital firms, accelerating access to global financing and investment networks, thereby advancing the translation of early-stage ideas into impactful global solutions.

In September 2025, Pfizer Inc. and BioNTech SE announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY(R) (COVID-19 Vaccine, mRNA) 2025-2026 Formula in adults aged 65 and older and in adults aged 18 through 64 with at least one underlying risk condition for severe COVID-19.

Types Covered:

• Oral Fluoroquinolones
• Injectable Fluoroquinolones
• Other Types

Spectrums Covered:

• Narrow-Spectrum
• Broad-Spectrum

Route of Administrations Covered:

• Oral
• Ophthalmic
• Intravenous
• Otic

Generations Covered:

• First Generation
• Second Generation
• Third Generation
• Fourth Generation

Indications Covered:

• Respiratory Tract Infections
• Ophthalmic Infections
• Urinary Tract Infections
• Gastrointestinal Infections
• Sexually Transmitted Diseases
• Skin and Soft Tissue Infections
• Other Indications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Fluoroquinolones Market, By Type

• 5.1 Introduction
• 5.2 Oral Fluoroquinolones
• 5.3 Injectable Fluoroquinolones
• 5.4 Other Types

6 Global Fluoroquinolones Market, By Spectrum

• 6.1 Introduction
• 6.2 Narrow-Spectrum
• 6.3 Broad-Spectrum

7 Global Fluoroquinolones Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Ophthalmic
• 7.4 Intravenous
• 7.5 Otic

8 Global Fluoroquinolones Market, By Generation

• 8.1 Introduction
• 8.2 First Generation
• 8.3 Second Generation
• 8.4 Third Generation
• 8.5 Fourth Generation

9 Global Fluoroquinolones Market, By Indication

• 9.1 Introduction
• 9.2 Respiratory Tract Infections
• 9.3 Ophthalmic Infections
• 9.4 Urinary Tract Infections
• 9.5 Gastrointestinal Infections
• 9.6 Sexually Transmitted Diseases
• 9.7 Skin and Soft Tissue Infections
• 9.8 Other Indications

10 Global Fluoroquinolones Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Bayer AG
• 12.2 Aurobindo Pharma
• 12.3 Pfizer Inc.
• 12.4 Dr. Reddy's Laboratories
• 12.5 Novartis AG
• 12.6 Glenmark Pharmaceuticals
• 12.7 Sanofi
• 12.8 Mylan N.V.
• 12.9 GlaxoSmithKline plc
• 12.10 Cipla Ltd.
• 12.11 Johnson & Johnson
• 12.12 Lupin Pharmaceuticals
• 12.13 Merck & Co., Inc.
• 12.14 Sun Pharmaceutical Industries Ltd.
• 12.15 Teva Pharmaceutical Industries Ltd.